Opinion|Videos|December 25, 2024

Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Key Takeaways

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.